January 23, 2024 03:03 PM EST
Pharma
Law

Gilead clos­es $247M HIV drug set­tle­ment deal

Nicole DeFeudis

Editor

A Cal­i­for­nia fed­er­al judge on Fri­day ap­proved a near­ly $247 mil­lion plan to set­tle claims that Gilead wrong­ful­ly kept gener­ic HIV com­peti­tors from the mar­ket …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

‭ Regulatory Lead / Head of Regulatory‬

Autonomy Bio Inc.

San Francisco, CA 94107, USA

TRENDING NOW

At AS­CO, cell ther­a­pies for dead­ly form of brain can­cer make ear­ly strides

Re­gen­eron makes $80M obe­si­ty deal with Han­soh

Kymera un­veils ‘ex­cep­tion­al’ Phase 1 da­ta for its Dupix­ent-in-a-pill pro­gram

Phase 3 or bust: Why Lil­ly won't run mid-stage can­cer tri­als

Q&A: San­doz CEO Richard Saynor on gener­ic GLP-1s, Trump's in­dus­try im­pact, and Mark Cuban's com­pa­ny

sponsored

Cy­ti­va and Eu­rek­aBio form strate­gic part­ner­ship to ad­vance lentivi­ral vec­tor man­u­fac­tur­ing for cell and gene ther­a­py ...

A service from the Financial Times